ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

This study is testing a combination of two drugs — ETC-159 (a WNT pathway inhibitor) and pembrolizumab (an immunotherapy) — in women with advanced ovarian cancer that has a specific genetic profile called MSS/pMMR. This cancer type typically does not respond well to immunotherapy alone, and ETC-159 aims to change that. **You may be eligible if...** - You are a woman aged 21 or older (at Singapore sites) - You have confirmed advanced or metastatic ovarian cancer - Your tumor has been tested and found to be MSS/pMMR (microsatellite stable) - Your disease progressed after platinum-based chemotherapy within 6 months, or platinum treatment is no longer an option - You have measurable disease on imaging - Your physical performance is adequate **You may NOT be eligible if...** - You have active autoimmune disease requiring systemic treatment - You have had prior treatment with ETC-159 or other WNT pathway inhibitors - You have bone conditions such as osteoporosis that make this study unsafe - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.